$105.06
0.27% today
Nasdaq, Sep 16, 08:31 pm CET
ISIN
US53220K5048
Symbol
LGND
Sector
Industry

Ligand Pharmaceuticals Incorporated Stock price

$104.77
+1.75 1.70% 1M
+32.01 43.99% 6M
+33.35 46.70% YTD
+42.04 67.02% 1Y
+23.53 28.97% 3Y
+45.35 76.31% 5Y
+74.02 240.66% 10Y
Nasdaq, Closing price Fri, Sep 13 2024
+2.67 2.62%
ISIN
US53220K5048
Symbol
LGND
Sector
Industry

Key metrics

Market capitalization $1.91b
Enterprise Value $1.69b
P/E (TTM) P/E ratio 45.32
EV/FCF (TTM) EV/FCF 37.42
EV/Sales (TTM) EV/Sales 12.70
P/S ratio (TTM) P/S ratio 14.34
P/B ratio (TTM) P/B ratio 2.45
Revenue growth (TTM) Revenue growth -28.55%
Revenue (TTM) Revenue $133.48m
EBIT (operating result TTM) EBIT $7.98m
Free Cash Flow (TTM) Free Cash Flow $45.29m
Cash position $226.93m
EPS (TTM) EPS $2.31
P/E forward 31.43
P/S forward 12.46
EV/Sales forward 11.03
Short interest 7.63%
Show more

Is Ligand Pharmaceuticals Incorporated a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

Ligand Pharmaceuticals Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:

Buy
100%

Financial data from Ligand Pharmaceuticals Incorporated

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
133 133
29% 29%
100%
- Direct Costs 44 44
44% 44%
33%
90 90
18% 18%
67%
- Selling and Administrative Expenses 22 22
20% 20%
17%
- Research and Development Expense 22 22
51% 51%
17%
45 45
27% 27%
34%
- Depreciation and Amortization 37 37
13% 13%
28%
EBIT (Operating Income) EBIT 7.98 7.98
210% 210%
6%
Net Profit 42 42
55% 55%
32%

In millions USD.

Don't miss a Thing! We will send you all news about Ligand Pharmaceuticals Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ligand Pharmaceuticals Incorporated Stock News

Neutral
Business Wire
10 days ago
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received full approval from the U.S. Food and Drug Administration (FDA) for FILSPARI® (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression. Ligand is entitled to milestone paym...
Neutral
GlobeNewsWire
17 days ago
Dublin, Aug. 30, 2024 (GLOBE NEWSWIRE) -- The "Global CD40 Ligand Market by Type (Monoclonal Antibody, Polyclonal Antibody), Application (Autoimmune Disease Treatment, Immunotherapy, Vaccine Development), End-Users - Forecast 2024-2030" report has been added to ResearchAndMarkets.com's offering. The CD40 Ligand Market size was estimated at USD 697.21 million in 2023, USD 734.50 million in 2024,...
Neutral
Business Wire
27 days ago
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on Tuesday, September 10, 2024, at 8:30 a.m. Eastern Time. Management is scheduled to host one-on-one meetings with investors a...
More Ligand Pharmaceuticals Incorporated News

Company Profile

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Head office United States
CEO Todd Davis
Employees 58
Founded 1987
Website www.ligand.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today